We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.83% | 64.79 | 64.30 | 64.85 | 65.53 | 64.33 | 65.51 | 7,822,721 | 05:00:04 |
From May 2019 to May 2024
By Kimberly Chin
Gilead Sciences Inc. (GILD) and Galapagos NV (GLPG) said an advanced phase of rheumatoid-arthritis trials proved efficacy after a 12-month study.
The results from Finch 1 and Finch 3 trials of filgotinib, an oral inhibitor that treats moderate to severe active rheumatoid arthritis, proved effective and safe in patients after a one-year study, the companies said.
Filgotinib hasn't been approved by regulatory authorities yet. The companies said they are awaiting approval of a marketing application for filgotinib by the European Medicines Agency, as well as approval of a new drug application with the Japanese Ministry of Health. Gilead said it intends to file a new drug application for the treatment with U.S. regulators later this year.
Galapagos and Gilead are globally collaborating on the development and commercialization of filgotinib. The FINCH Phase 3 studies are among several clinical trials of filgotinib for the treatment of inflammatory diseases.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
October 10, 2019 18:55 ET (22:55 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
